Publication: 3304

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
      QxMD      Google Scholar   
Citation:
Blood vol 136 (8) 936-945
Year:
2020
Type:
Manuscript
Funding:
AFT
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
9
Parents:
2856   3004   3165   3226   3401   3415  
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Janssen Research & Development, LLC  
Grants:
 
Corr. Author:
 
Authors:
                                                           
Networks:
CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OH008, OR013   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: